Tag: Intellia Therapeutics

Intellia Therapeutics shares are experiencing a dramatic downturn after a patient death in a pivotal clinical study triggered multiple analyst ...

A patient death during a critical Phase 3 study has triggered a severe downturn for gene-editing company Intellia Therapeutics. The ...

The investment landscape for Intellia Therapeutics has grown increasingly turbulent. A recent fatality within one of the company's clinical trials ...

Intellia Therapeutics shares experienced a severe downturn on Friday, plummeting 22.7% as investors reacted to a devastating combination of clinical, ...

A severe clinical setback has triggered a massive sell-off in Intellia Therapeutics stock, with shares plummeting more than 22% during ...

Intellia Therapeutics faced a severe market downturn following the disclosure of a patient death in a pivotal Phase 3 clinical ...

Intellia Therapeutics faces a pivotal juncture as the market anticipates its upcoming quarterly earnings release. The biotech firm's stock remains ...

A dramatic financial showdown is unfolding around Intellia Therapeutics, where extreme market pessimism collides with groundbreaking medical innovation. The biotech ...

The biotechnology sector has a new standout performer as Intellia Therapeutics demonstrates significant momentum across multiple fronts. Clinical trial progress, ...

The gene editing sector is witnessing remarkable developments as Intellia Therapeutics demonstrates groundbreaking progress with its CRISPR-based therapies. Within a ...